Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PHERGain
2016-002676-27Phase 2Active
- Sponsor
- MEDSIR
- Start
- Mar 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of trastuzumab and pertuzumab in breast cancer (3 cohorts), sponsored by MEDSIR. Started Mar 2017; status: active.
02
Drugs
trastuzumabpertuzumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2016-002676-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002676-27.